Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

August 11, 2025

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to address obesity and related health conditions.

Personalized and Patient-Centric Administration of Oral Medicines

August 11, 2025

New manufacturing methods are being explored, but challenges are still present in personalized medicine development.

Almirall Selects 2nd Dermatology Target in AI Drug Discovery Collaboration with Absci

August 08, 2025

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, functional antibody leads.

Lilly’s Oral GLP-1 Candidate Demonstrates 27-Pound Average Weight Loss in Phase III Trial

August 07, 2025

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Bora Pharmaceuticals to Expand Midwest Manufacturing Site

August 07, 2025

The investment will expand the company’s manufacturing and packaging capabilities at its Maple Grove, Minn. site, which Bora acquired in 2024 with its acquisition of Upsher-Smith Laboratories.

ESTEVE CDMO Acquires Regis Technologies

August 06, 2025

The acquisition expands the CDMO’s small-molecule API development and manufacturing services in the US.

Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease

August 05, 2025

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the decline of patients exhibiting early symptomatic Alzheimer’s disease.

The Evolving Field of Radiopharmaceuticals

August 04, 2025

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target tumors without impacting other cells in the body.

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

August 04, 2025

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.

Roche Reveals New Data from Alzheimer’s Disease Research at AAIC 2025

August 04, 2025

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical portfolios at this year’s AAIC.